Home › Funds › Tetragon Partners GP Ltd › AUTL
Tetragon Partners GP Ltd position in AUTL
AUTOLUS THERAPEUTICS LTD · Health Care
Tetragon Partners GP Ltd reported holding 9,500,000 shares of AUTL (AUTOLUS THERAPEUTICS LTD) in its Q2 2026 13F filing — a position valued at US$15.2M, representing 2.48% of its reported portfolio and ranking #3 among its reported holdings. Tetragon Partners GP Ltd has disclosed AUTL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Tetragon Partners GP Ltd's AUTL position evolved
Tetragon Partners GP Ltd first disclosed a stake in AUTL in Q3 2023 at 12,000,000 shares (US$28.0M). The position peaked in Q4 2023 at 8,000,000 shares, worth US$51.5M. Across 12 filings, Tetragon Partners GP Ltd increased the stake 4 time(s), trimmed it 2 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 9,500,000 shares valued at US$15.2M. Notable position changes include a 33% trim in Q4 2023 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 12.00M | $27.96M | New |
| Q4 2023 | 8.00M | $51.52M | Reduce |
| Q1 2024 | 7.53M | $48.01M | Reduce |
| Q2 2024 | 8.00M | $27.84M | Add |
| Q3 2024 | 8.00M | $29.04M | Hold |
| Q4 2024 | 8.25M | $19.39M | Add |
| Q1 2025 | 8.60M | $13.33M | Add |
| Q2 2025 | 9.50M | $21.66M | Add |
| Q3 2025 | 9.50M | $15.48M | Hold |
| Q4 2025 | 9.50M | $18.91M | Hold |
| Q1 2026 | 9.50M | $13.11M | Hold |
| Q2 2026 | 9.50M | $15.20M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AUTL and 13F data
AUTL (AUTOLUS THERAPEUTICS LTD) is a Health Care company. 18 other funds we track also report a position in AUTL — the largest reported positions include MAK CAPITAL ONE LLC (US$53.8M), Syncona Portfolio Ltd (US$26.6M), ARMISTICE CAPITAL, LLC (US$24.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AUTL
- MAK CAPITAL ONE LLC 33.62M sh · $53.79M · Q2 2026
- Syncona Portfolio Ltd 16.64M sh · $26.63M · Q2 2026
- ARMISTICE CAPITAL, LLC 15.00M sh · $24.00M · Q2 2026
- Frazier Life Sciences Management, L.P. 4.45M sh · $7.12M · Q2 2026
More on Tetragon Partners GP Ltd
FAQ
How long has Tetragon Partners GP Ltd held AUTL?
Tetragon Partners GP Ltd has disclosed AUTL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Tetragon Partners GP Ltd's current position in AUTL?
As of Q2 2026, Tetragon Partners GP Ltd holds 9.50M shares of AUTL (AUTOLUS THERAPEUTICS LTD), valued at $15.20M, representing 2.48% of its reported portfolio and ranking #3.
Has Tetragon Partners GP Ltd been buying or selling AUTL?
In the latest 13F filing (Q2 2026), Tetragon Partners GP Ltd held unchanged its position in AUTL. The position peaked in Q4 2023 at 8.00M shares.
Which other funds hold AUTL?
Other major institutional holders of AUTL include MAK CAPITAL ONE LLC, Syncona Portfolio Ltd, ARMISTICE CAPITAL, LLC, among 18 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.